Press release
Lawsuit filed for Investors who lost money with shares of Agenus Inc. (NASDAQ: AGEN)
A lawsuit was filed on behalf of investors in Agenus Inc. (NASDAQ: AGEN) shares over alleged securities laws violations.
Investors who purchased shares of Agenus Inc. (NASDAQ: AGEN) have certain options and for certain investors are short and strict deadlines running. Deadline: November 5, 2024. NASDAQ: AGEN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Lexington, MA based Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. Among other product candidates, the Company is developing balstilimab, an anti-PD-1 antagonist that has completed a Phase 2 clinical trial to treat second line cervical cancer; and botensilimab, an antigen 4 blocking antibody that is in a Phase 2 clinical trial for the treatment of pancreatic cancer and melanoma.
On July 18, 2024, Agenus Inc. (NASDAQ: AGEN) announced the results of an "end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM)." The press release revealed that the "FDA advised against submission of these results in support of an Accelerated Approval based on their view that objective response rates may not translate to survival benefit."
Shares of Agenus Inc. (NASDAQ: AGEN) declined from $19.69 per share on June 04, 2024, to as low as $4.41 per share on August 14, 2024.
The plaintiff claims that between January 23, 2023 and July 17, 2024, the Defendants made false and/or misleading statements and/or failed to disclose that the combination therapy of botensilimab and balstilimab was less effective than Defendants had led investors to believe, that accordingly, botensilimab and balstilimab's clinical results, as well as their regulatory and commercial prospects, were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Agenus Inc. (NASDAQ: AGEN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of Agenus Inc. (NASDAQ: AGEN) here
News-ID: 3668136 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation announced for Long-Term Investors in shares of Red Cat Holdings, I …
An investigation was announced for current long-term investors in shares of Red Cat Holdings, Inc. (NASDAQ: RCAT) concerning potential breaches of fiduciary duties by certain directors of Red Cat Holdings, Inc.
Investors who are current long term investors in Red Cat Holdings, Inc. (NASDAQ: RCAT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
Lawsuit was filed for Investors who lost money with shares in CTO Realty Growth, …
An investor, who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO), filed a lawsuit over alleged violations of Federal Securities Laws by CTO Realty Growth, Inc. in connection with certain allegedly false and misleading statements made between February 18, 2021 and June 24, 2025.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and for certain investors are short and strict deadlines running. Deadline: October…
Investigation announced for Long-Term Investors in shares of Fortrea Holdings In …
An investigation was announced for current long-term investors in shares of Fortrea Holdings Inc. (NASDAQ: FTRE) concerning potential breaches of fiduciary duties by certain directors of Fortrea Holdings Inc.
Investors who are current long term investors in Fortrea Holdings Inc. (NASDAQ: FTRE) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
Investigation announced for Long-Term Investors in shares of Organon & Co. (NYSE …
An investigation was announced for current long-term investors in shares of Organon & Co. (NYSE: OGN) concerning potential breaches of fiduciary duties by certain directors of Organon & Co.
Investors who are current long term investors in Organon & Co. (NYSE: OGN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
More Releases for Agenus
Vaccine Adjuvants Market Next Big Thing | Major Giants- GlaxoSmithKline, Novavax …
Archive Market Research published a new research publication on "Vaccine Adjuvants Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Vaccine Adjuvants market was mainly driven by the increasing R&D spending across the world.
Some of the key players profiled in…
Agenus Chooses Flex Databases for Enhanced Pharmacovigilance Solutions
Agenus, a global leader in biopharmaceuticals, has selected Flex Databases as its trusted partner for pharmacovigilance (PV) software, bringing cutting-edge technology and exceptional customer support to its clinical safety processes.
With over 26 years in the industry, Craig, a senior leader at Agenus, shared insights on why Flex Databases stood out among other eClinical providers. "Flex Databases went above and beyond to win our business," Craig said. "Unlike larger providers, Flex…
Sarcoma Therapeutics Market Is Booming Worldwide | Agenus, Agios, Eisai
The "Sarcoma Therapeutics Market" intelligence report, just published by USD Analytics Market, covers insurers' micro-level study of important market niches, product offers, and sales channels. In order to determine market size, potential, growth trends, and competitive environment, the Sarcoma Therapeutics Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the…
Therapeutic Vaccines Market Is Booming Worldwide with Agenus, Dendreon, Bavarian …
The "Global Therapeutic Vaccines" intelligence report, just published by USD Analytics, covers insurers' micro-level study of important market niches, product offers, and sales channels. In order to determine market size, potential, growth trends, and competitive environment, the Global Therapeutic Vaccines provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study…
Vaccine Adjuvants Market to See Promising Growth Ahead | Seppic , CSL Limited, A …
Global Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial), Regional Forecasts 2021-2027, The ' Vaccine Adjuvants market' research report added by Report Ocean, is an in-depth analysis of the latest developments, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research study provides market overview,…
Cancer Vaccines Market SWOT Analysis by Key Players: Advaxis, Advantagene, Agenu …
COVID-19 Outbreak-Global Cancer Vaccines Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the COVID-19 Outbreak-Global Cancer Vaccines Market. Some of the key players profiled…
